These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 10955453

  • 1. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL, Jamehdor MR, Arber JM.
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [Abstract] [Full Text] [Related]

  • 2. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [Abstract] [Full Text] [Related]

  • 3. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK, Tjan S, Parkes RK, O'Malley FP.
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ.
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [Abstract] [Full Text] [Related]

  • 7. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R, Apple SK, He J, Gornbein JA, Chang HR.
    Breast J; 2005 Feb; 11(6):433-9. PubMed ID: 16297088
    [Abstract] [Full Text] [Related]

  • 8. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.
    Breast J; 2005 Feb; 11(4):278-80. PubMed ID: 15982396
    [Abstract] [Full Text] [Related]

  • 9. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.
    Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW.
    Am J Clin Pathol; 2005 Aug; 124(2):273-81. PubMed ID: 16040300
    [Abstract] [Full Text] [Related]

  • 10. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [Abstract] [Full Text] [Related]

  • 11. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
    Falo C, Moreno A, Lloveras B, Figueras A, Varela M, Escobedo A.
    Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
    [Abstract] [Full Text] [Related]

  • 12. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
    Benöhr P, Henkel V, Speer R, Vogel U, Sotlar K, Aydeniz B, Reiser A, Neubauer H, Tabiti K, Wallwiener D, Clare SE, Kurek R.
    Anticancer Res; 2005 Oct; 25(3B):1895-900. PubMed ID: 16158923
    [Abstract] [Full Text] [Related]

  • 13. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival.
    Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML.
    Mol Diagn; 2000 Sep; 5(3):199-207. PubMed ID: 11070154
    [Abstract] [Full Text] [Related]

  • 14. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F, Jamal S, Nasir S.
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [Abstract] [Full Text] [Related]

  • 15. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting.
    Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A.
    Mod Pathol; 2001 Jul; 14(7):677-85. PubMed ID: 11455000
    [Abstract] [Full Text] [Related]

  • 16. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C.
    Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
    [Abstract] [Full Text] [Related]

  • 17. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K, Han S, Kim HJ, Kim J, Shin E.
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [Abstract] [Full Text] [Related]

  • 18. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
    Clin Cancer Res; 2005 Dec 01; 11(23):8348-57. PubMed ID: 16322295
    [Abstract] [Full Text] [Related]

  • 19. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A, Bronsard M, Lemieux R, Geha S.
    Ann Pathol; 2011 Dec 01; 31(6):472-9. PubMed ID: 22172120
    [Abstract] [Full Text] [Related]

  • 20. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
    Shin SJ, Hyjek E, Early E, Knowles DM.
    Int J Surg Pathol; 2006 Oct 01; 14(4):279-84. PubMed ID: 17041191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.